TY - JOUR
T1 - The silent burden of non-alcoholic fatty liver disease in the elderly
T2 - A global burden of disease analysis
AU - Danpanichkul, Pojsakorn
AU - Ng, Cheng Han
AU - Muthiah, Mark D.
AU - Duangsonk, Kwanjit
AU - Yong, Jie Ning
AU - Tan, Darren Jun Hao
AU - Lim, Wen Hui
AU - Wong, Zhen Yu
AU - Syn, Nicholas
AU - Tsusumi, Tsubasa
AU - Takahashi, Hirokazu
AU - Siddiqui, Mohammad Shadab
AU - Wong, Vincent Wai Sun
AU - Mantzoros, Christos S.
AU - Huang, Daniel Q.
AU - Noureddin, Mazen
AU - Loomba, Rohit
AU - Sanyal, Arun J.
AU - Wijarnpreecha, Karn
N1 - Publisher Copyright:
© 2023 John Wiley & Sons Ltd.
PY - 2023/11
Y1 - 2023/11
N2 - Background: Non-alcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The growing trend towards an aging population, along with an alarming rise in obesity and diabetes, may have significant implications for the burden of NAFLD. Aim: To assess the impact of NAFLD on the elderly. Methods: We utilised data from the Global Burden of Disease study between 2010 and 2019 to conduct a comprehensive analysis of the prevalence, mortality, and disability-adjusted life years (DALYs) associated with NAFLD in the elderly (65–89 years), stratified by region, nation, sociodemographic Index and sex. Results: Globally, there were an estimated 228 million cases, 87,230 deaths and 1.46 million DALYs attributed to NAFLD in the elderly. Geographically, the Western Pacific region had the highest burden of NAFLD in the elderly. From 2010 to 2019, there was an increasing prevalence rate in all areas, with the most pronounced change observed in the Western Pacific region (annual percentage change (APC) +0.95%, p < 0.001). Over the study period, there was a more rapid increase in NAFLD prevalence in men (APC +0.74%, p < 0.001) than in women (APC +0.63%, p < 0.001). In most regions, death and DALYs rates have declined, with the exception of the Americas, where there was a slight increase (APC +0.25%, p = 0.002 and 0.38%, p < 0.001, respectively). Conclusion: Over the past decade, the burden of NAFLD in the elderly has been increasing, necessitating immediate and inclusive measures to tackle the rising burden.
AB - Background: Non-alcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The growing trend towards an aging population, along with an alarming rise in obesity and diabetes, may have significant implications for the burden of NAFLD. Aim: To assess the impact of NAFLD on the elderly. Methods: We utilised data from the Global Burden of Disease study between 2010 and 2019 to conduct a comprehensive analysis of the prevalence, mortality, and disability-adjusted life years (DALYs) associated with NAFLD in the elderly (65–89 years), stratified by region, nation, sociodemographic Index and sex. Results: Globally, there were an estimated 228 million cases, 87,230 deaths and 1.46 million DALYs attributed to NAFLD in the elderly. Geographically, the Western Pacific region had the highest burden of NAFLD in the elderly. From 2010 to 2019, there was an increasing prevalence rate in all areas, with the most pronounced change observed in the Western Pacific region (annual percentage change (APC) +0.95%, p < 0.001). Over the study period, there was a more rapid increase in NAFLD prevalence in men (APC +0.74%, p < 0.001) than in women (APC +0.63%, p < 0.001). In most regions, death and DALYs rates have declined, with the exception of the Americas, where there was a slight increase (APC +0.25%, p = 0.002 and 0.38%, p < 0.001, respectively). Conclusion: Over the past decade, the burden of NAFLD in the elderly has been increasing, necessitating immediate and inclusive measures to tackle the rising burden.
KW - Male
KW - Humans
KW - Female
KW - Aged
KW - Non-alcoholic Fatty Liver Disease/epidemiology
KW - Global Burden of Disease
KW - Quality-Adjusted Life Years
KW - Prevalence
KW - Obesity/complications
KW - Global Health
UR - http://www.scopus.com/inward/record.url?scp=85170515781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170515781&partnerID=8YFLogxK
U2 - 10.1111/apt.17714
DO - 10.1111/apt.17714
M3 - Article
C2 - 37694808
SN - 0269-2813
VL - 58
SP - 1062
EP - 1074
JO - Alimentary Pharmacology & Therapeutics
JF - Alimentary Pharmacology & Therapeutics
IS - 10
ER -